| 3.64 -0.05 (-1.36%) | 08-28 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.57 | 1-year : | 5.34 |
| Resists | First : | 3.92 | Second : | 4.57 |
| Pivot price | 3.44  |
|||
| Supports | First : | 3.24 | Second : | 2.81 |
| MAs | MA(5) : | 3.68 |
MA(20) : | 3.34 |
| MA(100) : | 3.54 |
MA(250) : | 7.6 |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 71.3 |
D(3) : | 77.3 |
| RSI | RSI(14): 63.9 |
|||
| 52-week | High : | 20.63 | Low : | 2.49 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ IXHL ] has closed below upper band by 27.1%. Bollinger Bands are 26% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.75 - 3.77 | 3.77 - 3.79 |
| Low: | 3.51 - 3.54 | 3.54 - 3.56 |
| Close: | 3.6 - 3.64 | 3.64 - 3.68 |
Incannex Healthcare Limited is an Australian company dedicated to the research, development, and commercialization of medicinal cannabinoid products. The firm offers pharmaceutical-grade cannabinoid compounds under its proprietary Incannex brand. Its product pipeline includes several key assets: IHL-42X: This compound is currently undergoing Phase II clinical evaluation for the treatment of obstructive sleep apnea (OSA). Incannex partners with The Alfred Hospital and Novotech on this specific clinical program. IHL-216A: Designed to address traumatic brain injury (TBI). Furthermore, the Monash Trauma Group, part of Monash University's Department of Neuroscience, is conducting a study on IHL-216A's protective effects against sports-related concussions. IHL-675A: A unique formulation combining hydroxychloroquine and cannabidiol, developed for both the prevention and management of a range of inflammatory conditions. These include acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), asthma, bronchitis, rheumatoid arthritis, and inflammatory bowel diseases. Originally established in 2001 as Impression Healthcare Limited, the company officially changed its name to Incannex Healthcare Limited in June 2020. Incannex maintains its corporate headquarters in Sydney, Australia.
Tue, 25 Aug 2026
Incannex (IXHL) Advances Sleep Apnea Drug Trial Amid High Price-to-Sales Valuation - GuruFocus
Tue, 25 Aug 2026
Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X - The Manila Times
Tue, 25 Aug 2026
Sleep-apnea candidate showed up to 83% fewer breathing interruptions; Incannex doses first patient - Stock Titan
Wed, 15 Jul 2026
Incannex (IXHL) Secures U.S. Patent Grant in Obstructive Sleep Apnea for IHL-42X - Yahoo Finance
Mon, 08 Jun 2026
Biopharmaceutical company Incannex Healthcare Ltd (IXHL) receives inaugural coverage report from Alliance Global Partners. - Bitget
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 12 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 12.3 (%) |
| Held by Institutions | 3.8 (%) |
| Shares Short | 885 (K) |
| Shares Short P.Month | 509 (K) |
| EPS | -16.63 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.5 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -32.2 % |
| Return on Equity (ttm) | -117.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.07 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -18 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -0.22 |
| PEG Ratio | 0 |
| Price to Book value | 0.66 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.46 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|